Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 27:13:219.
doi: 10.25259/SNI_103_2022. eCollection 2022.

Prognostic factors following resection of intracranial metastases

Affiliations

Prognostic factors following resection of intracranial metastases

Duncan Henderson et al. Surg Neurol Int. .

Abstract

Background: The aim of this study was to identify prognostic factors associated with resection of intracranial metastases.

Methods: A retrospective case series including patients who underwent resection of cranial metastases from March 2014 to April 2021 at a single center. This identified 112 patients who underwent 124 resections. The median age was 65 years old (24-84) and the most frequent primary cancers were nonsmall cell lung cancer (56%), breast adenocarcinoma (13%), melanoma (6%), and colorectal adenocarcinoma (6%). Postoperative MRI with contrast was performed within 48 hours in 56% of patients and radiation treatment was administered in 41%. GraphPad Prism 9.2.0 was used for the survival analysis.

Results: At the time of data collection, 23% were still alive with a median follow-up of 1070 days (68-2484). The 30- and 90-day, and 1- and 5-year overall survival rates were 93%, 83%, 35%, and 17%, respectively. The most common causes of death within 90 days were as follows: unknown (32%), systemic or intracranial disease progression (26%), and pneumonia (21%). Age and extent of neurosurgical resection were associated with overall survival (P < 0.05). Patients aged >70 had a median survival of 5.4 months compared with 9.7, 11.4, and 11.4 for patients <50, 50-59, and 60-69, respectively. Gross-total resection achieved an overall survival of 11.8 months whereas sub-total, debulking, and unclear extent of resection led to a median survival of 5.7, 7.0, and 9.0 months, respectively.

Conclusion: Age and extent of resection are potential predictors of long-term survival.

Keywords: Brain metastasis; Breast cancer; Nonsmall cell lung cancer; Stereotactic radiosurgery; Whole-brain radiotherapy.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1:
Figure 1:
Kaplan–Meier graphs for survival analysis including all patients and then stratified by gender, age, and multiplicity of intracranial disease (median survivals and P values are displayed in Table 6).
Figure 2:
Figure 2:
Kaplan–Meier graph for survival analysis stratified by histological diagnosis, adjuvant radiation treatment, and extent of neurosurgical resection (median survivals and P values are displayed in Table 6).
Figure 3:
Figure 3:
Recursive partitioning analysis using age and extent of resection. GTR: Gross-total resection.
Supplementary Figure 1:
Supplementary Figure 1:
Bar charts showing multiplicity of intracranial disease, day postoperative MRI performed and extent of resection and adjuvant radiation treatment.

Similar articles

Cited by

References

    1. Al-Shamy G, Sawaya R. Management of brain metastases: The indispensable role of surgery. J Neurooncol. 2009;92:275–82. - PubMed
    1. Banfill KE, Bownes PJ, St Clair SE, Loughrey C, Hatfield P. Stereotactic radiosurgery for the treatment of brain metastases: Impact of cerebral disease burden on survival. Br J Neurosurg. 2012;26:674–8. - PubMed
    1. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049–60. - PMC - PubMed
    1. D’Andrea G, Palombi L, Minniti G, Pesce A, Marchetti P. Brain metastases: Surgical treatment and overall survival. World Neurosurg. 2017;97:169–77. - PubMed
    1. Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012;14:1171–7. - PMC - PubMed

LinkOut - more resources